학술논문
EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY
Document Type
Abstract
Author
Source
In Hematology, Transfusion and Cell Therapy October 2021 43 Supplement 1:S255-S255
Subject
Language
ISSN
2531-1379